AU Patent

AU2019297362B2 — Therapeutic heterocyclic compounds

Assigned to Gilead Sciences Inc · Expires 2022-05-26 · 4y expired

What this patent protects

Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:

USPTO Abstract

Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: AU2019297362B2
Jurisdiction: AU
Classification: —
Expires: 2022-05-26
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.